» Articles » PMID: 24249309

The Beneficial Effects of Postconditioning on No-reflow Phenomenon After Percutaneous Coronary Intervention in Patients with ST-elevation Acute Myocardial Infarction

Overview
Date 2013 Nov 20
PMID 24249309
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

No-reflow phenomenon is a serious complication of percutaneous coronary intervention (PCI) which is closely related to the incidence of major adverse cardiovascular events. It has been demonstrated that Postconditioning (PostC) during primary PCI confers protection against ischemia-reperfusion injury and thus might reduce infarct size. However, whether PostC may exert its beneficial effects on acute myocardial infarction (AMI) patients by reducing no-reflow phenomenon is still unknown. Sixty two patients diagnosed with ST-elevation AMI were randomly assigned to study group (n = 32) or control group (n = 30). Blood samples were obtained and assayed for creatine kinase MB (CK-MB) and high-sensitive C-reactive protein (hs-CRP). Determinants of reflow, including final thrombolysis in myocardial infarction (TIMI) grade-3 flow, ST-segment resolution (STR), myocardial blush grades-3 (MBG-3) and corrected thrombolysis in myocardial infarction frame count (cTFC), were comparative between the two groups. Compared with control group, more patients in study group were identified as the final TIMI grade-3 flow (81.3 vs. 56.7%, P = 0.036), MBG-3 (23 vs. 14%, P = 0.043) and STR ≥50% (93.8 vs. 73.3%, P = 0.029), while patients in study group had less cTFC (28.5 ± 9.1 vs. 37.4 ± 12.4, P = 0.002) After PCI, study group was associated with lower levels of CK-MB (2,397.6 ± 470.2 vs. 2,159.9 ± 485.5, P = 0.028), Troponin-I (197.5 ± 32.5 vs. 154 ± 43.1, P = 0.041) and hs-CRP (5.5 ± 4.5 vs. 9.5 ± 5.2 mg/L, P = 0.019) in comparison with control group. Left ventricle ejection fraction was better in the study group than in the control group (55.1 ± 9.8 vs. 42.9 ± 10.7, P = 0.042). PostC could improve myocardial reperfusion in patients with ST-elevation AMI undergoing PCI by reducing no-reflow. However, due to the limited sample size, the results of our study should not be considered conclusive.

Citing Articles

Effect of ischaemic postconditioning on markers of myocardial injury in ST-elevation myocardial infarction: a meta-analysis.

Bergman I, Gelikas S, Wexler Y, Braver O, Boyle D, Nussinovitch U Open Heart. 2024; 11(1).

PMID: 38286569 PMC: 10826564. DOI: 10.1136/openhrt-2023-002281.


The role and mechanisms of microvascular damage in the ischemic myocardium.

Zhao B, Ruze A, Zhao L, Li Q, Tang J, Xiefukaiti N Cell Mol Life Sci. 2023; 80(11):341.

PMID: 37898977 PMC: 11073328. DOI: 10.1007/s00018-023-04998-z.


Comparison of infarction size, complete ST-segment resolution incidence, mortality and re-infarction and target vessel revascularization between remote ischemic conditioning and ischemic postconditioning in ST-segment elevation myocardial infarction....

Zhang H, Yang L, Wang L Postepy Kardiol Interwencyjnej. 2021; 16(3):278-286.

PMID: 33597992 PMC: 7863805. DOI: 10.5114/aic.2020.99262.


Balloon Deflation Strategy during Primary Percutaneous Coronary Intervention in Acute ST-Segment Elevation Myocardial Infarction: A Randomized Controlled Clinical Trial and Numerical Simulation-Based Analysis.

Gu J, Zhuo Y, Liu T, Li J, Yin Z, Xu Z Cardiol Res Pract. 2020; 2020:4826073.

PMID: 32963824 PMC: 7492947. DOI: 10.1155/2020/4826073.


Effects of ischaemic postconditioning on outcomes of patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention: a meta-analysis.

Xing Z, Tang L, Huang J, Peng X, Hu X BMJ Open. 2019; 9(3):e022509.

PMID: 30904835 PMC: 6475223. DOI: 10.1136/bmjopen-2018-022509.


References
1.
Keeley E, Boura J, Grines C . Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003; 361(9351):13-20. DOI: 10.1016/S0140-6736(03)12113-7. View

2.
Braunwald E . Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded?. Circulation. 1989; 79(2):441-4. DOI: 10.1161/01.cir.79.2.441. View

3.
Chia S, Senatore F, Raffel O, Lee H, Wackers F, Jang I . Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2009; 1(4):415-23. DOI: 10.1016/j.jcin.2008.04.010. View

4.
Zeng M, Yan H, Chen Y, Zhao H, Lv Y, Liu C . Suppression of NF-κB reduces myocardial no-reflow. PLoS One. 2012; 7(10):e47306. PMC: 3467223. DOI: 10.1371/journal.pone.0047306. View

5.
Braunwald E, Kloner R . Myocardial reperfusion: a double-edged sword?. J Clin Invest. 1985; 76(5):1713-9. PMC: 424191. DOI: 10.1172/JCI112160. View